These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 23299842)

  • 1. Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark.
    Lee SJ; Boscardin WJ; Stijacic-Cenzer I; Conell-Price J; O'Brien S; Walter LC
    BMJ; 2013 Jan; 346():e8441. PubMed ID: 23299842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study.
    Rutter CM; Kim JJ; Meester RGS; Sprague BL; Burger EA; Zauber AG; Ergun MA; Campos NG; Doubeni CA; Trentham-Dietz A; Sy S; Alagoz O; Stout N; Lansdorp-Vogelaar I; Corley DA; Tosteson ANA
    Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):158-164. PubMed ID: 29150480
    [No Abstract]   [Full Text] [Related]  

  • 3. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force.
    Humphrey LL; Helfand M; Chan BK; Woolf SH
    Ann Intern Med; 2002 Sep; 137(5 Part 1):347-60. PubMed ID: 12204020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.
    Mandel JS; Church TR; Ederer F; Bond JH
    J Natl Cancer Inst; 1999 Mar; 91(5):434-7. PubMed ID: 10070942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to benefit for colorectal cancer screening: survival meta-analysis of flexible sigmoidoscopy trials.
    Tang V; Boscardin WJ; Stijacic-Cenzer I; Lee SJ
    BMJ; 2015 Apr; 350():h1662. PubMed ID: 25881903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test.
    Heresbach D; Manfredi S; D'halluin PN; Bretagne JF; Branger B
    Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):427-33. PubMed ID: 16538116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation.
    Nelson HD; Fu R; Cantor A; Pappas M; Daeges M; Humphrey L
    Ann Intern Med; 2016 Feb; 164(4):244-55. PubMed ID: 26756588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammography screening: a new estimate of number needed to screen to prevent one breast cancer death.
    Hendrick RE; Helvie MA
    AJR Am J Roentgenol; 2012 Mar; 198(3):723-8. PubMed ID: 22358016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of breast cancer mortality benefit and overdiagnosis adjusted for adherence: improving information on the effects of attending screening mammography.
    Jacklyn G; Glasziou P; Macaskill P; Barratt A
    Br J Cancer; 2016 May; 114(11):1269-76. PubMed ID: 27124337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of age in screening for cancer.
    Law MR; Morris JK; Wald NJ
    J Med Screen; 1999; 6(1):16-20. PubMed ID: 10321365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits and Harms of Breast Cancer Screening: A Systematic Review.
    Myers ER; Moorman P; Gierisch JM; Havrilesky LJ; Grimm LJ; Ghate S; Davidson B; Mongtomery RC; Crowley MJ; McCrory DC; Kendrick A; Sanders GD
    JAMA; 2015 Oct; 314(15):1615-34. PubMed ID: 26501537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast, Cervical, and Colorectal Cancer Screening Adherence: Effect of Low Body Mass Index in Women.
    Charkhchi P; Schabath MB; Carlos RC
    J Womens Health (Larchmt); 2020 Jul; 29(7):996-1006. PubMed ID: 31928405
    [No Abstract]   [Full Text] [Related]  

  • 14. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(1):1-32. PubMed ID: 23074501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for colorectal cancer using the faecal occult blood test, hemoccult.
    Towler BP; Irwig L; Glasziou P; Weller D; Kewenter J
    Cochrane Database Syst Rev; 2000; (2):CD001216. PubMed ID: 10796760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Get screened: a pragmatic randomized controlled trial to increase mammography and colorectal cancer screening in a large, safety net practice.
    Fiscella K; Yosha A; Hendren SK; Humiston S; Winters P; Ford P; Loader S; Specht R; Pope S; Adris A; Marcus S
    BMC Health Serv Res; 2010 Sep; 10():280. PubMed ID: 20863395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
    Colditz GA
    Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in colorectal cancer screening.
    Vu HT; Burke CA
    Curr Gastroenterol Rep; 2009 Oct; 11(5):406-12. PubMed ID: 19765369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The benefits and harms of breast cancer screening: an independent review.
    Independent UK Panel on Breast Cancer Screening
    Lancet; 2012 Nov; 380(9855):1778-86. PubMed ID: 23117178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing risks and benefits of colorectal cancer screening in elderly patients.
    Ko CW; Sonnenberg A
    Gastroenterology; 2005 Oct; 129(4):1163-70. PubMed ID: 16230070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.